Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers-Reference-Cited by-同舟云学术

Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers

Published:2024-08-29 Issue: Volume: Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Miyashita Naoyuki¹^ORCID,Nakamori Yasushi²,Ogata Makoto¹,Fukuda Naoki¹,Yamura Akihisa¹,Ito Tomoki¹

Affiliation:

1. First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Hirakata, Japan

2. Department of Emergency Medicine, Kansai Medical University Medical Center, Moriguchi, Japan

Abstract

ABSTRACT We evaluated the efficacy of ensitrelvir for the treatment of cough due to coronavirus disease 2019 Omicron variant in medical healthcare workers. A total of 633 patients were registered in this study: 206 patients chose ensitrelvir and 427 patients chose symptomatic treatment. Difference in score changes using the Leicester Cough Questionnaire between groups was 3.17 on day 4, 3.24 on day 7, and 2.46 on day 14. The analysis demonstrated a significant difference at all time points.

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01064-24

Reference13 articles.

1. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

2. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

3. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors

4. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

5. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study